Adare Pharma acquires oral formulations specialist Frontida BioPharm

The combined company intends to lead in the space of oral formulations, solving customers' complex formulation challenges

Customers will now be able to tap into Adare's new capabilities such as high potency compound handling and packaging services.

Together, the combined company will offer an expanded suite of solutions for complex oral formulations, such as taste masking, controlled release, high potency formulation manufacturing, and bioavailability enhancement.

The addition of Frontida brings Adare’s manufacturing footprint to seven sites spanning the US, Italy and France, and expands its integrated, end-to-end offering to its partners.

Vivek Sharma, CEO of Adare who will lead the combined organisation, said the acquistion will bolster Adare's ability to solve complex formulation challenges for its customers.

In April last year, Adare acquired Kansas-based pharmaceutical technology company Orbis Biosciences, whose platforms create drug particles that can be dosed in oral liquid, injectable, and otic dosage forms.